ERBB2 and breast carcinoma: EGFR/Her2 heterodimers play a key role in modulation of Tzm effects in Her2+ cell lines SK-BR3 and BT474 [58], while Her2/Axl heterodimerization is responsible for trastuzumab resistance in Her2+ breast cancer cell lines [59].